Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Synairgen makes progress with lung drug

Lung drug developer says tests showed success in treating idiopathic pulmonary fibrosis
Synairgen makes progress with lung drug
Syanairgen hopes to progress one of the Pharmaxis enzyme inhibitors to phase one trials next year

Respiratory drug group Synairgen plc (LON:SNG) has taken a step forward in developing a treatment for a fatal lung disease.

Synairgen announced positive results from its ongoing collaboration with Pharmaxis to develop a lysyl oxidase type 2 enzyme (LOXL2) inhibitor as a novel treatment for idiopathic pulmonary fibrosis (IPF).

IPF results from the build-up of scar tissue, or fibrosis, in the lungs, which prevents normal uptake of oxygen. There are more than 100,000 IPF sufferers in the US alone.

The results of the experiments showed that the Pharmaxis enzyme inhibitors, by inhibiting LOXL2, could reduce cross-linking of collagen fibres - which results in fibrosis.

Synairgen will now focus on the pharmacology of the inhibitors and expects to progress one of them to phase one clinical trials in 2017.

Chief executive Richard Marsden said: "We are very pleased with the progress made with this collaboration and are excited by these results.

"We look forward to updating the markets with further progress over the coming months."

Meanwhile, Synairgen announced losses from operations for the year to December 31 of £2.61mln against profits of £1.09mln a year ago.

The profit a year ago was driven by a one-off upfront licensing payment from AstraZeneca PLC (LON:AZN) of £4.25mln.

The group said its current funds would support the ongoing search and identification of new potential molecule opportunities.

Chairman Simon Shaw said: "We are pleased with the progress made this year across our collaborations and in screening new opportunities.

"Our primary asset, AZD-9412, is being progressed through the clinic by AstraZeneca with results expected in 2017.

"Our strong balance sheet positions us well for progressing further collaborative programmes during the coming year."

View full SNG profile View Profile

Synairgen plc Timeline

Related Articles

test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use